UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 109

Sortiert nach

Sialic acid–binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses

Cellular and molecular life sciences : CMLS, 2020-02, Vol.77 (4), p.593-605

2020

Link zum Volltext

Verfügbarkeit prüfen

B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma

Nature communications, 2019-09, Vol.10 (1), p.4186-14, Article 4186

2019

Link zum Volltext

Verfügbarkeit prüfen

Editorial: Novel roles for tumor-associated neutrophils

Frontiers in immunology, 2022-08, Vol.13, p.1004772-1004772

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeted glycan degradation potentiates the anticancer immune response in vivo

Nature chemical biology, 2020-12, Vol.16 (12), p.1376

2020

Link zum Volltext

Verfügbarkeit prüfen

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer

The Journal of pathology, 2020-01, Vol.250 (1), p.19-29

2020

Link zum Volltext

Verfügbarkeit prüfen

Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis

Frontiers in immunology, 2019-09, Vol.10, p.2120-2120

2019

Link zum Volltext

Verfügbarkeit prüfen

Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer

Proceedings of the National Academy of Sciences - PNAS, 2014-09, Vol.111 (39), p.14211-14216

2014

Link zum Volltext

Verfügbarkeit prüfen

Unraveling the impact of a glyco-immune checkpoint in bone metastasis

Proceedings of the National Academy of Sciences - PNAS, 2024-02, Vol.121 (9), p.e2400499121

Läubli, Heinz

2024

Link zum Volltext

Verfügbarkeit prüfen

A red meat-derived glycan promotes inflammation and cancer progression

Proceedings of the National Academy of Sciences - PNAS, 2015-01, Vol.112 (2), p.542-547

2015

Link zum Volltext

Verfügbarkeit prüfen

PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade

Cancer Immunology, Immunotherapy, 2020-08, Vol.69 (8), p.1505-1517

2020

Link zum Volltext

Verfügbarkeit prüfen

Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes

Blood, 2009-11, Vol.114 (20), p.4583-4591

2009

Link zum Volltext

Verfügbarkeit prüfen

Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy

Nature communications, 2023-02, Vol.14 (1), p.86-86, Article 86

2023

Link zum Volltext

Verfügbarkeit prüfen

Lectin Galactoside-binding Soluble 3 Binding Protein (LGALS3BP) Is a Tumor-associated Immunomodulatory Ligand for CD33-related Siglecs

The Journal of biological chemistry, 2014-11, Vol.289 (48), p.33481-33491

2014

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol

BMC cancer, 2024-01, Vol.24 (1), p.82-82, Article 82

2024

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions

Swiss medical weekly, 2018-05, Vol.148, p.w14625

2018

Link zum Volltext

Verfügbarkeit prüfen

speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing

Nature communications, 2022-11, Vol.13 (1), p.6555-6555, Article 6555

2022

Link zum Volltext

Verfügbarkeit prüfen

Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation

Swiss medical weekly, 2019-11, Vol.149, p.w20150

2019

Link zum Volltext

Verfügbarkeit prüfen

A Standardized Analysis of Tertiary Lymphoid Structures in Human Melanoma: Disease Progression- and Tumor Site-Associated Changes With Germinal Center Alteration

Frontiers in immunology, 2021-06, Vol.12, p.675146-675146

2021

Link zum Volltext

Verfügbarkeit prüfen

Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events

Journal for immunotherapy of cancer, 2018-05, Vol.6 (1), p.40-40, Article 40

2018

Link zum Volltext

Verfügbarkeit prüfen

Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia

Nature communications, 2024-02, Vol.15 (1), p.993-993, Article 993

2024

Link zum Volltext

Verfügbarkeit prüfen

Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies

Proceedings of the National Academy of Sciences - PNAS, 2014-04, Vol.111 (16), p.5998-6003

2014

Link zum Volltext

Verfügbarkeit prüfen

Siglec receptors impact mammalian lifespan by modulating oxidative stress

eLife, 2015-04, Vol.4

2015

Link zum Volltext

Verfügbarkeit prüfen

The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity

Expert opinion on therapeutic targets, 2019-10, Vol.23 (10), p.839-853

2019

Link zum Volltext

Verfügbarkeit prüfen

Targeting sialic acid–Siglec interactions to reverse immune suppression in cancer

Glycobiology (Oxford), 2018-09, Vol.28 (9), p.640-647

2018

Link zum Volltext

Verfügbarkeit prüfen

Glycosaminoglycans in cancer therapy

American Journal of Physiology: Cell Physiology, 2022-06, Vol.322 (6), p.C1187-C1200

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(96)

Publikationsform

Sprache

Englisch
(108)
Japanisch
(18)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Sialic acid–binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses

B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma

Editorial: Novel roles for tumor-associated neutrophils

Targeted glycan degradation potentiates the anticancer immune response in vivo

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer

Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis

Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer

Unraveling the impact of a glyco-immune checkpoint in bone metastasis

A red meat-derived glycan promotes inflammation and cancer progression

PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade

Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes

Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy

Lectin Galactoside-binding Soluble 3 Binding Protein (LGALS3BP) Is a Tumor-associated Immunomodulatory Ligand for CD33-related Siglecs

A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol

Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions

speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing

Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation

A Standardized Analysis of Tertiary Lymphoid Structures in Human Melanoma: Disease Progression- and Tumor Site-Associated Changes With Germinal Center Alteration

Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events

Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia

Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies

Siglec receptors impact mammalian lifespan by modulating oxidative stress

The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity

Targeting sialic acid–Siglec interactions to reverse immune suppression in cancer

Glycosaminoglycans in cancer therapy

Suchergebnisse filtern